Abstract
Tumour blood vessels differ from their normal counterparts for reasons that have received little attention. We report here that they are of at least six distinct types, we describe how each forms, and, looking forward, encourage the targeting of tumour vessel subsets that have lost their vascular endothelial growth factor-A (VEGF-A) dependency and so are likely unresponsive to anti-VEGF-A therapies.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Blood Vessels / pathology
-
Capillaries / pathology
-
Capillaries / physiopathology
-
Humans
-
Neoplasms / blood supply*
-
Neovascularization, Pathologic / drug therapy
-
Neovascularization, Pathologic / etiology*
-
Neovascularization, Pathologic / pathology
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / physiology
Substances
-
Vascular Endothelial Growth Factor A